Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees.

GlobeNewsWire • Sep 10, 2026

Fortrea to Participate in September Investor Conferences

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:

GlobeNewsWire • Sep 10, 2026

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets

GlobeNewsWire • Sep 2, 2026

Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion

Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million.

Benzinga • Sep 2, 2026

Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue

Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG&A fell faster than sales. Net new business awards increased ~19% YoY, with a trailing-12-month book-to-bill ratio of 1.12x, but revenue conversion remains uncertain.

Seeking Alpha • Aug 30, 2026

Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentum

Fortrea Holdings Inc. (FTRE) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research • Jul 31, 2026

Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know

Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research • Jul 31, 2026

FTRE vs. ARGX: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jul 31, 2026

Best Momentum Stock to Buy for July 31st

FTRE, ASML and KLAC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2026.

Zacks Investment Research • Jul 31, 2026

Fortrea Q2 Earnings Call Highlights

Fortrea NASDAQ: FTRE reported second-quarter 2026 revenue of $678.2 million and adjusted EBITDA of $58.7 million, while raising its full-year revenue and adjusted EBITDA outlook. Management said results reflected stronger clinical pharmacology performance, cost-savings initiatives and improving commercial activity, particularly among biotechnology clients.

MarketBeat • Jul 29, 2026